Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q2

2160.TEDINET S100P1F0
Period2022-01-01 → 2022-06-30
Filed2022-08-15
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥8.2bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.2bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥6.5bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥2.6bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income¥1.0bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥526m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥682m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax¥790m2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥443m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥522m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥676m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥325m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥941m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥509m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥198m2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥126m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥745m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥309m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥35.3bnat 2022-06-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.0bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥13.5bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥21.8bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.1bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.0bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥17.9bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥14.5bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥389m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.5bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥1.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥267m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥2.9bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥14.252022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.862022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥20.32021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥10.782021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥14.182022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.832022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥19.732021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥10.592021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.5%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.9%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-06-30¥1.2bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-06-30¥526m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-06-30¥7.0bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-06-30¥479m
—segment totalrevenue2022-01-01 → 2022-06-30¥8.2bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥8.2bn
—segment totalsegment profit2022-01-01 → 2022-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-06-30¥1.0bn
jpcrp040300-q2r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-06-30¥390m
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-06-30¥5.5bn
jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-06-30¥1.1bn
—segment totalrevenue2021-01-01 → 2021-06-30¥6.5bn
—segment totalrevenue external2021-01-01 → 2021-06-30¥6.5bn
—segment totalsegment profit2021-01-01 → 2021-06-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 734
ItemContextValueUnit
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember-278058000JPY
Equity IFRSCurrentQuarterInstant21762501000JPY
Profit loss before tax IFRSPrior1YTDDuration1197676000JPY
Profit loss before tax IFRSCurrentYTDDuration790388000JPY
Depreciation expense ope cf IFRSPrior1YTDDuration181290000JPY
Depreciation expense ope cf IFRSCurrentYTDDuration239814000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration212197000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration-472879000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-141721000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration161555000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-156306000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-150680000JPY
Bonus allowance ope cf IFRSPrior1YTDDuration-1682000JPY
Bonus allowance ope cf IFRSCurrentYTDDuration-21543000JPY
Finance income and finance costs ope cf IFRSPrior1YTDDuration260267000JPY
Finance income and finance costs ope cf IFRSCurrentYTDDuration358503000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration-3077000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration335458000JPY
Subtotal ope cf IFRSPrior1YTDDuration1548644000JPY
Subtotal ope cf IFRSCurrentYTDDuration1240618000JPY
Interest received ope cf IFRSPrior1YTDDuration30378000JPY
Interest received ope cf IFRSCurrentYTDDuration26272000JPY
Interest paid ope cf IFRSPrior1YTDDuration-17687000JPY
Interest paid ope cf IFRSCurrentYTDDuration-6492000JPY
Income taxes refund paid ope cf IFRSPrior1YTDDuration-460479000JPY
Income taxes refund paid ope cf IFRSCurrentYTDDuration-871133000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration1100855000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration389264000JPY
Net decrease increase in time deposits inv cf IFRSPrior1YTDDuration-831500000JPY
Net decrease increase in time deposits inv cf IFRSCurrentYTDDuration-948500000JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-140763000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-202521000JPY
Proceeds from sale of property plant and equipment inv cf IFRSPrior1YTDDuration332000JPY
Proceeds from sale of property plant and equipment inv cf IFRSCurrentYTDDuration－JPY
Purchase of intangible assets inv cf IFRSPrior1YTDDuration-42920000JPY
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-348338000JPY
Increase of rent deposit inv cf IFRSPrior1YTDDuration-550000JPY
Increase of rent deposit inv cf IFRSCurrentYTDDuration-261000JPY
Decrease of rent deposit inv cf IFRSPrior1YTDDuration－JPY
Decrease of rent deposit inv cf IFRSCurrentYTDDuration441000JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration6786000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration2371000JPY
Other inv cf IFRSPrior1YTDDuration1739000JPY
Other inv cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-1006877000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-1496808000JPY
Net increase decrease in short term borrowings fin cf IFRSPrior1YTDDuration-663537000JPY
Net increase decrease in short term borrowings fin cf IFRSCurrentYTDDuration-200000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-50000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass